ArticleBone & joint research2026
Ultrasound combined with voriconazole for treating acute fungal periprosthetic joint infection caused by Candida albicans : an in vitro and in vivo experimental study.
Article in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aims: Currently, fungal periprosthetic joint infection (FPJI) following joint arthroplasty remains a major therapeutic challenge worldwide. Therefore, this study aims to investigate a novel and promising therapeutic approach. Methods: In the in vitro experiment, ultrasound and voriconazole (VOR) were used alone or in combination against Results: In vitro, the combination of ultrasound and VOR showed the most pronounced antifungal effect. In vivo, IA VOR injection is better for maintaining high local VOR concentrations. Based on this, the combination of ultrasound and IA VOR demonstrated superior outcomes across multiple endpoints, including serum biochemical markers, weightbearing scores, reactive bone changes, inflammation, and local knee skin temperature, as well as reduced colony counts on soft tissues, bone, and implants. In contrast, IV VOR showed minimal improvement across these parameters. Moreover, in rats subjected to any VOR and ultrasound treatment, no pathological changes in major metabolic organs or abnormal serum markers were observed. Additionally, no skin pathological changes were found after ultrasound exposure. Conclusion: The combination of ultrasound and IA injection of VOR represents a novel and promising therapeutic strategy for
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.